Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Literature DB >> 26884375

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Marc S Raab¹, Nicola Lehners¹, Jing Xu¹, Anthony D Ho², Peter Schirmacher³, Hartmut Goldschmidt⁴, Mindaugas Andrulis³.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2016 PMID： 26884375 DOI： 10.1182/blood-2015-12-686782

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

28 in total

Review 1. Novel Agents in Multiple Myeloma.

Authors: Raphaël Szalat; Nikhil C Munshi
Journal: Cancer J Date: 2019 Jan/Feb Impact factor: 3.360

Review 2. Tracking myeloma tumor DNA in peripheral blood.

Authors: Johannes M Waldschmidt; Tushara Vijaykumar; Birgit Knoechel; Jens G Lohr
Journal: Best Pract Res Clin Haematol Date: 2020-01-14 Impact factor: 3.020

Review 3. Molecular basis of clonal evolution in multiple myeloma.

Authors: Yusuke Furukawa; Jiro Kikuchi
Journal: Int J Hematol Date: 2020-02-06 Impact factor: 2.490

Review 4. [Predictive molecular pathological stratification of hematological neoplasms].

Authors: M Andrulis
Journal: Pathologe Date: 2016-11 Impact factor: 1.011

5. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authors: N Bolli; G Biancon; M Moarii; S Gimondi; Y Li; C de Philippis; F Maura; V Sathiaseelan; Y-T Tai; L Mudie; S O'Meara; K Raine; J W Teague; A P Butler; C Carniti; M Gerstung; T Bagratuni; E Kastritis; M Dimopoulos; P Corradini; K Anderson; P Moreau; S Minvielle; P J Campbell; E Papaemmanuil; H Avet-Loiseau; N C Munshi
Journal: Leukemia Date: 2017-12-06 Impact factor: 11.528

6. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Authors: Matteo Claudio Da Vià; Antonio Giovanni Solimando; Andoni Garitano-Trojaola; Santiago Barrio; Umair Munawar; Susanne Strifler; Larissa Haertle; Nadine Rhodes; Eva Teufel; Cornelia Vogt; Constantin Lapa; Andreas Beilhack; Leo Rasche; Hermann Einsele; K Martin Kortüm
Journal: Oncologist Date: 2019-10-18

7. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Authors: L Rasche; S S Chavan; O W Stephens; P H Patel; R Tytarenko; C Ashby; M Bauer; C Stein; S Deshpande; C Wardell; T Buzder; G Molnar; M Zangari; F van Rhee; S Thanendrarajan; C Schinke; J Epstein; F E Davies; B A Walker; T Meissner; B Barlogie; G J Morgan; N Weinhold
Journal: Nat Commun Date: 2017-08-16 Impact factor: 14.919

8. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Authors: Leo Rasche; Edgardo J Angtuaco; Terri L Alpe; Grant H Gershner; James E McDonald; Rohan S Samant; Manoj Kumar; Rudy Van Hemert; Joshua Epstein; Shayu Deshpande; Ruslana Tytarenko; Shmuel Yaccoby; Jens Hillengass; Sharmilan Thanendrarajan; Carolina Schinke; Frits van Rhee; Maurizio Zangari; Brian A Walker; Bart Barlogie; Gareth J Morgan; Faith E Davies; Niels Weinhold
Journal: Blood Date: 2018-05-21 Impact factor: 22.113

9. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

Authors: Bachisio Ziccheddu; Giulia Biancon; Filippo Bagnoli; Chiara De Philippis; Francesco Maura; Even H Rustad; Matteo Dugo; Andrea Devecchi; Loris De Cecco; Marialuisa Sensi; Carolina Terragna; Marina Martello; Tina Bagratuni; Efstathios Kastritis; Meletios A Dimopoulos; Michele Cavo; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Niccolo Bolli
Journal: Blood Adv Date: 2020-03-10

10. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.